Last reviewed · How we verify
Ilaprazole tablet
Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Ilaprazole tablet |
|---|---|
| Also known as | Ilaprazole Placebo-matching tablet |
| Sponsor | Livzon Pharmaceutical Group Inc. |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Ilaprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and allows healing of acid-related lesions. It is a benzimidazole-based PPI with a rapid onset and extended duration of action.
Approved indications
- Gastric ulcer
- Duodenal ulcer
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Dizziness
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer (PHASE3)
- The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers (PHASE4)
- Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD (PHASE3)
- Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. (PHASE4)
- Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients (PHASE3)
- IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients (PHASE2)
- Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients (PHASE3)
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilaprazole tablet CI brief — competitive landscape report
- Ilaprazole tablet updates RSS · CI watch RSS
- Livzon Pharmaceutical Group Inc. portfolio CI